Home Topics Genome Editing Scribe Pursues CRISPR Therapies with Expanded Biogen Collaboration

Scribe 10.8.20 307 — A year and a half into a collaboration with Biogen to develop CRISPR-based therapies, Scribe Therapeutics says the companies have made progress beyond the little that they have announced publicly. Scribe disclosed last week that Biogen had exercised an option for a second target through which they aim to treat disease [Scribe Therapeutics]

Scribe Pursues CRISPR Therapies with Expanded Biogen Collaboration

CEO Benjamin Oakes discusses his company’s progress toward developing genome editing treatments

By Alex Philippidis

May 12, 2022

A year and a half into a collaboration with Biogen to develop CRISPR-based therapies, Scribe Therapeutics says the companies have made progress beyond the little that they have announced publicly. Scribe disclosed last week that Biogen had exercised an option for a second target through which they aim to treat disease [Scribe Therapeutics]

Headquartered in Alameda, CA, Scribe develops CRISPR-based treatments through its genetic modification platform, designed to build and apply its suite of CRISPR technologies in therapeutic areas that include neurodegenerative diseases; ophthalmological diseases; multi-system, muscle, and metabolic disorders; and hematopoietic disorders. That platform aims to address safety, delivery, poor editing outcomes, and the long-running bitter legal battle over who invented CRISPR-Cas9. To avoid intellectual property uncertainty, Scribe has engineered its own CRISPR effectors . . .